We have established proprietary MHRA licensed manufacturing capabilities and a supply chain model that enables us to leverage a pipeline of internal and partnered programs around our lead asset, EBX-101. We operate sites in Aberdeen and Glasgow, Scotland.

Our leadership team have substantial experience in bringing products through the full development pathway from the lab to successful clinical studies. We are united by our collective desire to change the standard of care for patients battling debilitating diseases associated with the microbiome. 

Our Board of Directors are all highly accomplished biopharmaceutical executives that each have a successful track record in delivering value building milestones for shareholders, including multiple trade sales.